CN1144801A - β-肾上腺素能兴奋剂 - Google Patents

β-肾上腺素能兴奋剂 Download PDF

Info

Publication number
CN1144801A
CN1144801A CN96105900A CN96105900A CN1144801A CN 1144801 A CN1144801 A CN 1144801A CN 96105900 A CN96105900 A CN 96105900A CN 96105900 A CN96105900 A CN 96105900A CN 1144801 A CN1144801 A CN 1144801A
Authority
CN
China
Prior art keywords
compound
prodrug
alkyl
formula
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN96105900A
Other languages
English (en)
Chinese (zh)
Inventor
R·E·陶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Pfizer Inc
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN1144801A publication Critical patent/CN1144801A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
CN96105900A 1995-05-10 1996-05-07 β-肾上腺素能兴奋剂 Pending CN1144801A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002220538A CA2220538A1 (en) 1995-05-10 1995-05-10 .beta.-adrenergic agonists
WOPCT/IB95/0344 1995-05-10
PCT/IB1995/000342 WO1996035670A1 (en) 1995-05-10 1995-05-10 β-ADRENERGIC AGONISTS

Publications (1)

Publication Number Publication Date
CN1144801A true CN1144801A (zh) 1997-03-12

Family

ID=25679804

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96105900A Pending CN1144801A (zh) 1995-05-10 1996-05-07 β-肾上腺素能兴奋剂

Country Status (6)

Country Link
EP (1) EP0828712A1 (ja)
JP (1) JPH11504648A (ja)
CN (1) CN1144801A (ja)
CA (1) CA2220538A1 (ja)
FI (1) FI974170A (ja)
WO (1) WO1996035670A1 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981562A (en) * 1996-01-30 1999-11-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE69735433D1 (de) 1996-11-14 2006-05-04 Pfizer Verfahren zur herstellung von substituierten pyridinen
US6001856A (en) * 1997-06-13 1999-12-14 Pfizer Inc. β-adrenergic agonists to reduce a wasting condition
AU735249B2 (en) * 1997-07-03 2001-07-05 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds having saturated rings and medicinal compositions containing the same
EP0920864A1 (en) * 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
DK1277736T3 (da) 2000-04-28 2007-10-01 Asahi Kasei Pharma Corp Hidtil ukendte bicykliske forbindelser
KR100622461B1 (ko) 2001-10-25 2006-09-19 아사히 가세이 파마 가부시키가이샤 2환식 화합물
KR20060124603A (ko) * 2003-11-03 2006-12-05 베링거 인겔하임 인터내셔날 게엠베하 베타-3-아드레날린 수용체 효능제 및 알파 길항제 및/또는5-알파-리덕타제 억제제를 함유하는 약제학적 조성물
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
CN102171191A (zh) 2008-10-09 2011-08-31 旭化成制药株式会社 吲唑衍生物
CA2740772A1 (en) 2008-10-09 2010-04-15 Asahi Kasei Pharma Corporation Indazole compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) * 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
EP0105053B1 (en) * 1982-10-01 1988-01-20 Merck & Co. Inc. Aralkylaminoethanol heterocyclic compounds
GB8703007D0 (en) * 1987-02-10 1987-03-18 Glaxo Group Ltd Chemical compounds
US5019578A (en) * 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
NZ226991A (en) * 1987-11-27 1992-03-26 Merck & Co Inc Alpha-heterocyclically-substituted ethanolamines and use as animal growth promotors
US5726192A (en) * 1992-12-29 1998-03-10 Smithkline Beecham Corporation Platelet aggregation inhibiting compounds
NZ265692A (en) * 1993-06-14 1997-02-24 Pfizer Indole- and benzofuran- containing hydroxyamines and analogs; pharmaceutical compositions

Also Published As

Publication number Publication date
FI974170A0 (fi) 1997-11-07
JPH11504648A (ja) 1999-04-27
FI974170A (fi) 1997-11-07
WO1996035670A1 (en) 1996-11-14
EP0828712A1 (en) 1998-03-18
CA2220538A1 (en) 1996-11-14

Similar Documents

Publication Publication Date Title
US5859044A (en) β-adrenergic agonists
US5977124A (en) β-adrenergic agonists
CN1144801A (zh) β-肾上腺素能兴奋剂
US5843972A (en) Heterocyclic β-adrenergic agonists
AU617139B2 (en) New phenylethanolamines
US6706743B2 (en) β3 adrenergic receptor agonists and uses thereof
MXPA97008621A (en) Agonistasó-adrenergicos, compositions that contain and use of mis
MXPA97002601A (en) Agonistasó-adrenergicos heterocicli
CN1148350C (zh) 新型VLA-4抑制剂:oMePUPA-V
CN1890223A (zh) 辣椒素受体促效剂
CN1653063A (zh) (s)－4－氨基－5－氯－2－甲氧基－n－[1－[1－(2－四氢呋喃羰基)－4－哌啶甲基]－4－哌啶基]苯甲酰胺及其制备方法、含有该化合物的药物组合物及其中间体
US8273881B2 (en) Phenazine compounds and use thereof in autoimmune and inflammatory diseases
CN1564686A (zh) 8－氨基－[1,2,4]三唑并[1,5－a]吡啶－6－甲酰胺
US20050075323A1 (en) Beta3 adrenergic receptor agonists and uses thereof
CN1067068C (zh) 用作速激肽受体拮抗剂的杂环取代的哌嗪酮衍生物
CN1050380A (zh) 新的取代烷基哌啶及其作为胆固醇合成抑制剂的应用
US6689800B2 (en) β3-adrenergic receptor agonist crystal forms, processes for the production thereof, and uses thereof
CN1886370A (zh) N－酰基－n′－苄基－亚烷基二氨基衍生物
MXPA97005815A (es) Agonistasó-adrenergicos
AU4747599A (en) Intermediates for the preparation of beta-adrenergic agonists
CN1886364A (zh) 选择性过氧化物酶体增殖物激活受体调节剂
CN1886366A (zh) 环戊基衍生物
WO2003072571A1 (en) Salt of a pyridyl ethanolamine derivative and its use as a beta-3-adrenergic receptor agonist
NZ227196A (en) Phenylethanolamine derivatives and their pharmaceutical and veterinary compositions

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1040245

Country of ref document: HK